Iovance Biotherapeutics to Host Conference Call to Discuss Second Quarter 2017 Financial and Operating Results on Tuesday, Au...
July 25 2017 - 8:00AM
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology
company developing novel cancer immunotherapies based on
tumor-infiltrating lymphocyte (TIL) technology, today announced
that it will report its second quarter 2017 financial and operating
results after the close of the U.S. financial markets on Tuesday,
August 1, 2017. Management will host a conference call and live
audio webcast to discuss these results and provide a business
update at 5:00 p.m. ET.
In order to participate in the conference call, please dial
1-844-646-4465 (domestic) or 1-615-247-0257 (international) and
reference the access code 47307932. The live webcast can be
accessed under “News & Events” in the “Investors” section of
the Company’s website at http://www.iovance.com/ or you may use the
link: http://edge.media-server.com/m/p/so22t2sr.
A replay of the call will be available one hour after the end of
the call on August 1, 2017 until 8:00 p.m. ET on August 31, 2017.
To access the replay, please dial 1-855-859-2056 (domestic) or
1-404-537-3406 (international) and reference the access code
47307932. The archived webcast will be available for thirty days in
the Investors section of Iovance Biotherapeutics’ website at
http://www.iovance.com/.
About Iovance Biotherapeutics, Inc.Iovance
Biotherapeutics, Inc. is a clinical-stage biotechnology company
focused on the development of cancer immunotherapy products for the
treatment of various cancers. The Company's lead product candidate
is an adoptive cell therapy using tumor-infiltrating lymphocyte
(TIL) technology being investigated for the treatment of patients
with refractory metastatic melanoma, recurrent and/or metastatic
squamous cell carcinoma of the head and neck and cervical cancer.
For more information, please visit http://www.iovance.com.
Investor Contact:
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah@sternir.com
Media Contact:
Media Relations Contact:
Evan Smith/Kotaro Yoshida
FTI Consulting
212-850-5622/212-850-5690
evan.smith@fticonsulting.com
kotaro.yoshida@fticonsulting.com
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Apr 2023 to Apr 2024